Weight-loss med gets FDA nod—for liver disease
Industry Buzz
“[The] decision by the FDA reflects the continued progress in how we understand and treat patients with MASH, bringing us closer to care that meets the needs of people living with this disease." — Arun Sanyal, MD, director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University
The FDA has expanded the indication for semaglutide to include adults with noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH), opening a new avenue in the management of a notoriously challenging condition. []
This approval follows mounting evidence supporting GLP-1 receptor agonists not just for weight management, but also for their potential metabolic and hepatic benefits.
Why this matters
MASH affects millions of adults in the US and until now, therapeutic options have been frustratingly limited. Noncirrhotic patients often face progression toward cirrhosis, cardiovascular complications, and diabetes-related morbidity.
By targeting weight and metabolic dysfunction simultaneously, semaglutide offers a dual approach that could shift clinical practice for patients with both obesity and liver disease.
“[The] decision by the FDA reflects the continued progress in how we understand and treat patients with MASH, bringing us closer to care that meets the needs of people living with this disease,” Arun Sanyal, MD, director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, said in a press release. []
Evidence behind the approval
The FDA’s decision was informed by trials showing that semaglutide improves liver histology in patients with MASH without cirrhosis.
Improvements in steatosis, inflammation, and hepatocyte ballooning were observed alongside significant weight loss and better glycemic control.
While long-term outcomes, including fibrosis regression, remain under investigation, the results mark a meaningful step forward in disease modification.
Considerations for your practice
Patient selection: The approval is limited to adults with noncirrhotic MASH. Careful staging to confirm the absence of advanced fibrosis is essential.
Comorbidity management: Many patients will have obesity, type 2 diabetes, or metabolic syndrome. Wegovy can serve as a bridge therapy addressing multiple metabolic risk factors simultaneously.
Monitoring: Baseline liver function tests and continued monitoring are recommended. Gastroenterologists and primary care providers should coordinate on dosing, adherence, and adverse event management.
For adults with obesity and confirmed noncirrhotic MASH, consider semaglutide as part of a comprehensive management plan, along with a reduced calorie diet and increased physical activity.
Early intervention may help slow disease progression while also supporting weight reduction and metabolic health—critical factors in improving long-term outcomes.
Related: Is Ozempic the 'biggest thing since penicillin'? Physicians weigh in